US Patent

US8058069 — Lipid formulations for nucleic acid delivery

Formulation · Assigned to Protiva Biotherapeutics Inc · Expires 2029-04-15 · 3y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects novel, stable lipid particles for delivering nucleic acids, such as interfering RNA, and methods for making and administering them.

USPTO Abstract

The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.

Drugs covered by this patent

Patent Metadata

Patent number
US8058069
Jurisdiction
US
Classification
Formulation
Expires
2029-04-15
Drug substance claim
No
Drug product claim
Yes
Assignee
Protiva Biotherapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.